Experience of etiotropic therapy of acute respiratory viral infection with domestic antiviral drug
Objective. To assess the efficacy, safety, and tolerability of riamilovir in patients diagnosed with acute respiratory viral infections (ARVI) and to determine an optimal dose of the drug.
Patients and methods. The study included 165 patients with non-complicated mild to moderate laboratory confirmed ARVI (no antigens of influenza virus were detected). All patients signed an informed consent before their inclusion into the study. Participants were randomized into 3 groups at a 1:1:1 ratio (55 patients in each group). One hundred sixty-one patients completed the study according to the protocol.
Results. We registered no adverse reactions associated with the drug and resulted it its cessation. Our findings suggest high efficacy, safety, and good tolerability of riamilovir.
Conclusion. Riamilovir can be recommended for phase III trials (at a dose of 500 mg/day (100 mg 5 times a day) and 750 mg/day (250 mg 3 times a day)) to compare its efficacy with other causal treatments.
Key words: causal treatment of ARVI, riamilovir.
For citation: Tokin I.I., Zubkova T.G., Drozdova Yu.V., Lioznov D.A. Experience of etiotropic therapy of acute respiratory viral infection with domestic antiviral drug. Infekc. bolezni (Infectious diseases). 2019; 17(4): 13–17. (In Russian).